Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 7/2016

28.01.2016 | Original Article

Evaluation of 68Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1

verfasst von: Clément Morgat, Fritz-Line Vélayoudom-Céphise, Paul Schwartz, Martine Guyot, Delphine Gaye, Delphine Vimont, Jürgen Schulz, Joachim Mazère, Marie-Laure Nunes, Denis Smith, Elif Hindié, Philippe Fernandez, Antoine Tabarin

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Context

Somatostatin receptor scintigraphy with 111In-pentetreotide (SRS) is used to detect duodenopancreatic neuroendocrine tumors (dpNETs) in multiple endocrine neoplasia type 1 (MEN1). However, SRS has limited sensitivity for this purpose. Positron emission tomography/computed tomography (PET/CT) with 68Ga-DOTA-TOC has a higher rate of sporadic dpNETs detection than SRS but there is little data for dpNETs detection in MEN1.

Purpose

To compare the performances of 68Ga-DOTA-TOC PET/CT, SRS and contrast-enhanced computed tomography (CE-CT) to diagnose dpNETs in MEN1.

Design and setting

Single-institution prospective comparative study

Patients and methods

Nineteen consecutive MEN1 patients (aged 47 ± 13 years) underwent 68Ga-DOTA-TOC PET/CT, SRS, and CE-CT within 2 months in random order. Blinded readings of images were performed separately by experienced physicians. Unblinded analysis of CE-CT, combined with additional magnetic resonance imaging, endoscopic-ultrasound, 18F-2-fluoro-deoxy-d-glucose (18F-FDG) PET/CT or histopathology results served as reference standard for dpNETs diagnosis.

Results

The sensitivity of 68Ga-DOTA-TOC PET/CT, SRS, and CE-CT was 76, 20, and 60 %, respectively (p < 0.0001). All the true-positive lesions detected by SRS were also depicted on 68Ga-DOTA-TOC PET/CT. 68Ga-DOTA-TOC PET/CT detected lesions of smaller size than SRS (10.7 ± 7.6 and 15.2 ± 5.9 mm, respectively, p < 0.03). False negatives of 68Ga-DOTA-TOC PET/CT included small dpNETs (<10 mm) and 18F-FDG PET/CT positive aggressive dpNETs. No false positives were recorded. In addition, whole-body mapping with 68Ga-DOTA-TOC PET/CT identified extra-abdominal MEN1-related tumors including one neuroendocrine thymic carcinoma identified by the three imaging procedures, one bronchial carcinoid undetected by CE-CT and three meningiomas undetected by SRS.

Conclusions

Owing to higher diagnostic performance, 68Ga-DOTA-TOC PET/CT (or alternative 68Ga-labeled somatostatin analogues) should replace 111In-pentetreotide in the investigation of MEN1 patients.
Literatur
1.
Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404–7.CrossRefPubMed
2.
Machens A, Schaaf L, Karges W, Frank-Raue K, Bartsch DK, Rothmund M, et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol. 2007;67(4):613–22.
3.
Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011.CrossRefPubMed
4.
Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P, et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34(2):249–55.CrossRefPubMed
5.
Pieterman CRC, Conemans EB, Dreijerink KMA, de Laat JM, Timmers HTM, Vriens MR, et al. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis. Endocr Relat Cancer. 2014;21(3):R121–42.CrossRefPubMed
6.
Öberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010;139(3):742–53.e1.CrossRefPubMed
7.
Johnbeck CB, Knigge U, Kjær A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10(14):2259–77.CrossRefPubMed
8.
Kowalski J, Henze M, Schuhmacher J, Macke H, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using 68Ga-DOTA-DPhe1-Tyr3-octreotide in comparison to 111In-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5(1):42–8.CrossRefPubMed
9.
Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34(10):1617–26.CrossRefPubMed
10.
Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48(4):508–18.CrossRefPubMed
11.
Froeling V, Elgeti F, Maurer M, Scheurig-Muenkler C, Beck A, Kroencke T, et al. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. Ann Nucl Med. 2012;26(9):738–43.CrossRefPubMed
12.
Sharma P, Mukherjee A, Karunanithi S, Naswa N, Kumar R, Ammini AC, et al. Accuracy of 68Ga DOTANOC PET/CT imaging in patients with multiple endocrine neoplasia syndromes. Clin Nucl Med. 2015;40(7):e351–6.CrossRefPubMed
13.
Sadowski SM, Millo C, Cottle-Delisle C, Merkel R, Yang LA, Herscovitch P, et al. Results of 68Gallium-DOTATATE PET/CT scanning in patients with multiple endocrine neoplasia Type 1. J Am Coll Surg. 2015;221(2):509–17.CrossRefPubMed
14.
Lastoria S, Marciello F, Faggiano A, Aloj L, Caracò C, Aurilio M et al. Role of 68Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). Endocrine. 2015.
15.
Velikyan I, Beyer GJ, Langstrom B. Microwave-supported preparation of 68Ga bioconjugates with high specific radioactivity. Bioconjug Chem. 2004;15(3):554–60.CrossRefPubMed
16.
Morgat C, Mazère J, Fernandez P, Buj S, Vimont D, Schulz J, et al. A phantom-based method to standardize dose-calibrators for new β+-emitters. Nucl Med Commun. 2015;36(2):201–6.CrossRefPubMed
17.
Bombardieri E, Ambrosini V, Aktolun C, Baum R, Bishof-Delaloye A, Del Vecchio S, et al. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010;37(7):1441–8.CrossRefPubMed
18.
van Asselt SJ, Brouwers AH, van Dullemen HM, van der Jagt EJ, Bongaerts AHH, Kema IP, et al. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointest Endosc. 2015;81(1):159–67.e2.CrossRefPubMed
19.
Barbe C, Murat A, Dupas B, Ruszniewski P, Tabarin A, Vullierme M-P, et al. Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. Dig Liver Dis. 2012;44(3):228–34.CrossRefPubMed
20.
Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: somatostatin receptor imaging with 111in-pentetreotide. Neuroendocrinology. 2009;90(2):184–9.CrossRefPubMed
21.
Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Shalom R, Engel A, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf). 2003;59(5):565–73.CrossRef
22.
Ambrosini V, Campana D, Tomassetti P, Fanti S. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging. 2012;39(S1):52–60.CrossRef
23.
Schreiter NF, Bartels A-M, Froeling V, Steffen I, Pape U-F, Beck A, et al. Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT. Radiol Oncol. 2014;48(4):339–47.CrossRefPubMedPubMedCentral
24.
Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini JL, Richard B, et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab. 2003;88(11):5353–60.CrossRefPubMed
25.
Scarsbrook AF, Thakker RV, Wass JAH, Gleeson FV, Phillips RR. Multiple endocrine neoplasia: spectrum of radiologic appearances and discussion of a multitechnique imaging approach. RadioGraphics. 2006;26(2):433–51.CrossRefPubMed
26.
Abgral R, Leboulleux S, Déandreis D, Aupérin A, Lumbroso J, Dromain C, et al. Performance of 18fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab. 2011;96(3):665–71.CrossRefPubMed
27.
Squires III M, Volkan Adsay N, Schuster D, Russell M, Cardona K, Delman K, et al. Octreoscan versus FDG-PET for neuroendocrine tumor staging: a biological approach. Ann Surg Oncol. 2015;22(7):2295–301.CrossRefPubMed
28.
Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard A-S, Bouriel C, et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med. 2009;50(6):858–64.CrossRefPubMed
29.
Ruf J, Schiefer J, Furth C, Kosiek O, Kropf S, Heuck F, et al. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J Nucl Med. 2011;52(5):697–704.CrossRefPubMed
30.
Eberlein U, Lassmann M. Dosimetry of 68Ga-labeled compounds. Appl Radiat Isot. 2013;76:70–4.CrossRefPubMed
31.
Schreiter N, Brenner W, Nogami M, Buchert R, Huppertz A, Pape U-F, et al. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(1):72–82.CrossRefPubMed
32.
Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2014;55(4):389–98.CrossRefPubMed
33.
Pfeifer A, Knigge U, Binderup T, Mortensen J, Oturai P, Loft A, et al. 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-Octreotide in 112 patients. J Nucl Med. 2015;56(6):847–54.CrossRefPubMed
34.
Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103(44):16436–41.CrossRefPubMedPubMedCentral
35.
Morgat C, Mishra AK, Varshney R, Allard M, Fernandez P, Hindie E. Targeting neuropeptide receptors for cancer imaging and therapy: perspectives with bombesin, neurotensin, and neuropeptide-Y receptors. J Nucl Med. 2014;55:1650–7.CrossRefPubMed
Metadaten
Titel
Evaluation of 68Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1
verfasst von
Clément Morgat
Fritz-Line Vélayoudom-Céphise
Paul Schwartz
Martine Guyot
Delphine Gaye
Delphine Vimont
Jürgen Schulz
Joachim Mazère
Marie-Laure Nunes
Denis Smith
Elif Hindié
Philippe Fernandez
Antoine Tabarin
Publikationsdatum
28.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2016
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3319-3

Weitere Artikel der Ausgabe 7/2016

European Journal of Nuclear Medicine and Molecular Imaging 7/2016 Zur Ausgabe

Original Article

Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes

Erratum

Erratum to: 18F-FDG PET/MRI evaluation of retroperitoneal fibrosis: a simultaneous multiparametric approach for diagnosing active disease

Erratum

Erratum to: EANM '15 Annual Congress of the European Association of Nuclear Medicine, October 10–14, 2015, Hamburg, Germany

Book Review

Cumali Aktolun and Stanley J. Goldsmith (Eds): Nuclear Oncology

Image of the Month

Malignant phaeochromocytoma with cavoatrial extension imaged with 123I-MIBG

Original Article

Malignancy rate of biopsied suspicious bone lesions identified on FDG PET/CT